Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. S&P 500 (SPY)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 892.14K | 730.34K | 1.49M | 1.31M | 1.42M | Gross Profit |
| -1.12M | -1.62M | -568.62K | 497.08K | 584.64K | EBIT |
| -9.12M | -6.37M | -4.98M | -3.08M | -2.00M | EBITDA |
| -8.40M | -7.55M | -4.56M | -2.77M | -1.70M | Net Income Common Stockholders |
| -6.38M | -6.23M | -4.97M | -2.86M | -1.74M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.64M | 6.03M | 2.11M | 5.60M | 2.37M | Total Assets |
| 10.88M | 10.08M | 5.40M | 8.60M | 5.55M | Total Debt |
| 316.39K | 64.09K | 0.00 | 69.05K | 132.84K | Net Debt |
| -6.32M | -5.96M | -2.11M | -5.54M | -2.23M | Total Liabilities |
| 1.63M | 1.75M | 2.00M | 990.19K | 1.12M | Stockholders Equity |
| 9.41M | 8.38M | 3.39M | 7.61M | 4.44M |
| Cash Flow | Free Cash Flow | |||
| -6.00M | -6.91M | -3.67M | -2.41M | -1.97M | Operating Cash Flow |
| -5.59M | -5.69M | -3.54M | -2.21M | -384.51K | Investing Cash Flow |
| -388.02K | -1.17M | -129.46K | -191.00K | -1.59M | Financing Cash Flow |
| 6.59M | 10.77M | 176.10K | 5.64M | 2.82M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$1.54B | 10.93 | 51.39% | ― | -8.06% | -10.13% | |
72 Outperform | $9.91B | 193.11 | 14.52% | ― | 55.85% | 893.42% | |
54 Neutral | AU$204.99M | ― | -37.20% | ― | ― | 32.02% | |
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
44 Neutral | AU$51.76M | ― | -131.55% | ― | 12.53% | -11.04% | |
39 Underperform | AU$133.36M | ― | -35.20% | ― | 4.68% | -155.42% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories Ltd. has announced a Share Purchase Plan following a successful placement of shares to sophisticated and institutional investors, raising approximately $4 million. The funds will be used to launch Promarker tests in Australia and the USA, upgrade systems for clinical diagnostics, and establish laboratory platforms, with the total expected proceeds reaching $5.5 million. The plan offers eligible shareholders the opportunity to purchase additional shares at a discounted price, with the potential to raise an additional $1 million.
Proteomics International Laboratories Ltd has announced a correction to the date of its upcoming Extraordinary General Meeting, now scheduled for Friday, 30 May 2025. The company encourages shareholders to participate by lodging proxy votes online and updating their communication preferences to receive future documents electronically, reflecting a move towards more digital engagement with stakeholders.
Proteomics International Laboratories Ltd has announced an Extraordinary General Meeting scheduled for 30 May 2025. The company is encouraging shareholders to participate by lodging their proxy votes online, emphasizing the importance of digital communication and efficiency. This meeting is a significant event for stakeholders, as it may involve decisions impacting the company’s strategic direction and operations.
Proteomics International Laboratories Ltd has issued 10,810,811 ordinary shares without disclosure under the Corporations Act, as per their notice under Section 708A(5)(e). The company has confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information required to be disclosed. This issuance reflects the company’s ongoing operations and compliance, potentially impacting its financial positioning and stakeholder interests.
Proteomics International Laboratories Ltd announced the issuance of 5,405,399 unquoted securities, set to expire on May 31, 2026, with an exercise price of $0.50. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move may impact the company’s financial structure and provide additional capital for its ongoing projects.
Proteomics International Laboratories Ltd has announced the application for quotation of 10,810,811 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning positively.
Proteomics International Laboratories Ltd has issued a prospectus for the offer of new options, targeting placement participants, directors, key management personnel, joint lead managers, and SPP participants. This strategic move is aimed at raising capital, which could enhance the company’s operational capabilities and market position. The options are considered highly speculative, and the company advises potential investors to seek professional advice before participating. The offer is limited to applicants within Australia and New Zealand, aligning with the company’s continuous disclosure obligations under the Corporations Act.
Proteomics International Laboratories Ltd announced significant advancements in its operations, including the launch of the PromarkerD predictive test for diabetic kidney disease in Australia, which outperforms conventional tests. The company also opened a CLIA certified reference laboratory in California and secured a new Australian patent for its OxiDx technology. These developments are part of Proteomics International’s strategy to commercialize its suite of precision diagnostic tests, leveraging the growing telehealth market and direct-to-consumer healthcare trends to enhance its industry positioning and offer scalable, cost-effective diagnostic solutions.
Proteomics International Laboratories Ltd has announced a proposed issue of securities, including options expiring in May 2026 and ordinary fully paid shares, with a total of 16,216,216 securities to be issued. This move is likely aimed at raising capital to support the company’s ongoing research and development efforts, potentially enhancing its market position and providing value to stakeholders.
Proteomics International Laboratories Ltd has successfully secured A$4.5 million through a placement to institutional and sophisticated investors to support the commercial launch of its Promarker diagnostic tests in the US and Australia. The funds will be used to launch PromarkerD, PromarkerEso, and PromarkerEndo tests, upgrade systems for clinical diagnostics in Australia, and establish laboratory platforms in the USA, enhancing the company’s market positioning in precision diagnostics.
Proteomics International Laboratories Ltd has requested a trading halt on its securities on the Australian Securities Exchange as it prepares to release an announcement regarding a capital raise and subsequent issue of securities. This move indicates a strategic financial maneuver that could impact the company’s market operations and potentially affect its stakeholders.
Proteomics International Laboratories Ltd announced that its Managing Director, Dr. Richard Lipscombe, and Chief Commercial Officer, Mr. Phillip Prather, will present at the Morgan Stanley Alpha ex-100 Conference in Sydney. This participation underscores the company’s active engagement with investors and highlights its leadership in the field of predictive diagnostics, potentially enhancing its market visibility and stakeholder interest.
Proteomics International Laboratories Ltd has announced the formation of a Clinical Advisory Board for its PromarkerEso blood test, aimed at detecting esophageal adenocarcinoma. This board, composed of leading clinicians and researchers, will provide strategic guidance to support the global commercialization of PromarkerEso, a test that addresses a significant health issue given the rising prevalence of esophageal adenocarcinoma worldwide. The board’s expertise is expected to enhance the company’s research, development, and commercial efforts, positioning Proteomics International as a leader in the field of esophageal cancer diagnostics.
Proteomics International Laboratories Ltd announced that its subsidiary, OxiDx Pty Ltd, has secured a second-generation Australian patent for its OxiDx oxidative stress diagnostic test, which is valid until 2039. The test, which uses a simple fingerprick blood sample to detect oxidative stress, is gaining interest from sectors such as high-performance sports and horse racing. The company plans to launch the test in Australia in mid-2025 and subsequently expand into the US. This patent strengthens the commercial value of the OxiDx technology, which is already protected in the USA, Japan, and Europe, and pending in other jurisdictions. The OxiDx test is significant as oxidative stress is linked to over 70 health conditions, including muscle injuries that account for a substantial portion of sports injuries.
Proteomics International Laboratories Ltd announced its participation in the WA Life Sciences Broker Meets Biotech event, where Dr. Richard Lipscombe will present a suite of diagnostic tests ready for launch. This presentation underscores the company’s commitment to advancing its position in the biotech industry and highlights its ongoing efforts to innovate in the field of predictive diagnostics, potentially benefiting stakeholders by improving disease treatment options.
Proteomics International Laboratories Ltd announced that their PromarkerD test has been validated through publication in the journal Diagnostics, proving its superiority over conventional tests in identifying the risk of diabetes-related chronic kidney disease. This development is expected to enhance the company’s market position by potentially revolutionizing diabetic kidney disease risk assessment and management, offering significant implications for healthcare stakeholders.
Proteomics International Laboratories Ltd has launched Promarker®D, a predictive test for diabetic kidney disease, in Australia, coinciding with World Kidney Day. This test, which can predict the onset of chronic kidney disease up to four years in advance for diabetes patients, is expected to significantly impact healthcare by enabling early intervention and potentially reducing the incidence of kidney failure. The launch in Australia is part of a broader global commercialization strategy, with plans to expand into the USA and European markets, supported by a new laboratory in California.
Proteomics International Laboratories Ltd announced that its PromarkerD test significantly outperforms standard tests in predicting kidney decline in type 2 diabetes, as published in the journal Diagnostics. This advancement could revolutionize diabetic kidney disease management, offering earlier intervention and reducing healthcare costs, with the potential to impact over 537 million people worldwide. The company has opened a Reference Laboratory in California and plans to launch PromarkerD in Australia, initially through a direct-to-consumer approach.
Proteomics International Laboratories Ltd reported a 29% increase in revenue from operating and other activities for the half-year ending December 31, 2024, reaching $962,000. Despite the revenue growth, the company experienced an 18% increase in net loss, amounting to $4.503 million. The financial report highlights a reduction in net cash outflow from operating and investing activities, while cash and cash equivalents stood at $5.325 million by the end of the period. These financial results indicate ongoing challenges in achieving profitability, but also reflect improved cash management and operational efficiency.